跳至主要内容
临床试验/CTRI/2015/01/005409
CTRI/2015/01/005409已完成4 期

A Multicentric open label non-interventional post marketing Surveillance study to evaluate safety and tolerability of BEâ??s inactivated vero cell derived Japanese Encephalitis vaccine in â?¥1 to â?¤3 year old healthy children in a two dose schedule. - None

Biological ELimited0 个研究点目标入组 800 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • 1.Subjects of either sex who are between >=1 to <=3 years at the time of 1st vaccination
  • 2.Written informed consent obtained prior to screening from subjectâ??s Parents/Guardian or the legally acceptable representative (LAR)
  • 3.Free of clinically significant health problems as established by medical history and physical examination before entering into the study
  • 4.Ability of the subjectâ??s Parents/Guardian or the legally acceptable representative (LAR) to understand and comply with the requirements of the protocol

排除标准

  • 1.Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine.
  • 2.Any family history of Immunodeficiency or autoimmune disease.
  • 3.Administration of chronic (defined as more than 14 days) immune-suppressants or other immune-modifying drugs within 6 months of vaccination. (For corticosteroids, this meant prednisone, or equivalent, >=0.05 mg/kg/day. Topical and inhaled steroids allowed).
  • 4.History of severe hypersensitivity reactions (in particular to a component of the investigational vaccine, anaphylaxis or severe cases of atopy requiring emergency treatment or hospital admission).
  • 5.Any confirmed or suspected Infection with HIV, HCV and Hepatitis B (HBsAg).
  • 6.Subjects with history of severe cardiopulmonary, hepatobiliary / renal disorders and or malignancy.
  • 7.Any acute infection within two weeks prior to enrolment.
  • 8.Inability or unwillingness by the subjectâ??s parent/guardian or legally acceptable representative(s) to provide informed consent and to abide by the requirements of the study.
  • 9.Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion.

研究者

发起方
Biological ELimited

相似试验